CN104520707B - 糖尿病生物标记物 - Google Patents

糖尿病生物标记物 Download PDF

Info

Publication number
CN104520707B
CN104520707B CN201380027247.6A CN201380027247A CN104520707B CN 104520707 B CN104520707 B CN 104520707B CN 201380027247 A CN201380027247 A CN 201380027247A CN 104520707 B CN104520707 B CN 104520707B
Authority
CN
China
Prior art keywords
cells
cell
diabetes
cd45ro
cd62l
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380027247.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104520707A (zh
Inventor
泰汉摩·欧尔本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orban Biotech LLC
Original Assignee
Orban Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech LLC filed Critical Orban Biotech LLC
Publication of CN104520707A publication Critical patent/CN104520707A/zh
Application granted granted Critical
Publication of CN104520707B publication Critical patent/CN104520707B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380027247.6A 2012-05-24 2013-05-24 糖尿病生物标记物 Expired - Fee Related CN104520707B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
US61/651,144 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Publications (2)

Publication Number Publication Date
CN104520707A CN104520707A (zh) 2015-04-15
CN104520707B true CN104520707B (zh) 2018-03-27

Family

ID=49621783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380027247.6A Expired - Fee Related CN104520707B (zh) 2012-05-24 2013-05-24 糖尿病生物标记物

Country Status (13)

Country Link
US (5) US20130316375A1 (cg-RX-API-DMAC10.html)
EP (2) EP2856149B1 (cg-RX-API-DMAC10.html)
JP (5) JP6312332B2 (cg-RX-API-DMAC10.html)
KR (1) KR102172285B1 (cg-RX-API-DMAC10.html)
CN (1) CN104520707B (cg-RX-API-DMAC10.html)
AU (4) AU2013266145A1 (cg-RX-API-DMAC10.html)
CA (1) CA2874507A1 (cg-RX-API-DMAC10.html)
DK (1) DK2856149T3 (cg-RX-API-DMAC10.html)
ES (1) ES2810227T3 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN10259A (cg-RX-API-DMAC10.html)
MX (1) MX357169B (cg-RX-API-DMAC10.html)
WO (1) WO2013177505A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201409006B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN107003315B (zh) * 2014-12-25 2018-09-25 株式会社日立制作所 胰岛素分泌能力分析装置、具备该装置的胰岛素分泌能力分析系统以及胰岛素分泌能力分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
EP3433612B1 (en) * 2016-03-22 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
JP7852926B2 (ja) 2020-06-26 2026-04-28 ファイム ファーマ リミテッド 乾癬及び他の自己免疫疾患抗原免疫モジュレータ（ａｉｍ）治療プラットフォーム
WO2022264088A1 (en) 2021-06-17 2022-12-22 Phaim Pharma Ltd. Individualized cell therapy using patient-derived antigen-specific regulatory t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246212A1 (en) * 2005-09-30 2009-10-01 Kyoto University Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
JP7618502B2 (ja) * 2021-05-14 2025-01-21 東京計器株式会社 船舶用自動操舵装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BALB/c小鼠1型糖尿病模型的构建与CD4+ CD25+Treg的检测;刘繁荣等;《广东医学》;20110228;第32卷(第4期);427-429 *
I型糖尿病患者外周血辅助性T细胞亚群Th1/Th2细胞平衡研究;石晓红;《齐鲁医学检验》;20041231;第15卷(第1期);8-9 *
成人隐匿性自身免疫糖尿病CD4+调节性T细胞研究;杨治芳等;《中华医学杂志》;20090926;第86卷(第36期);2533-2536 *

Also Published As

Publication number Publication date
EP3767295A1 (en) 2021-01-20
JP6312332B2 (ja) 2018-04-18
ZA201409006B (en) 2016-07-27
JP2023011814A (ja) 2023-01-24
AU2013266145A1 (en) 2015-01-15
US20190137483A1 (en) 2019-05-09
AU2023222980A1 (en) 2023-09-21
DK2856149T3 (da) 2020-08-17
KR102172285B1 (ko) 2020-11-02
US20250237643A1 (en) 2025-07-24
JP2018116061A (ja) 2018-07-26
JP2021001899A (ja) 2021-01-07
AU2019200824A1 (en) 2019-04-04
US20230333094A1 (en) 2023-10-19
EP2856149A1 (en) 2015-04-08
AU2019200824B2 (en) 2021-06-24
CA2874507A1 (en) 2013-11-28
IN2014DN10259A (cg-RX-API-DMAC10.html) 2015-08-07
ES2810227T3 (es) 2021-03-08
JP2024150702A (ja) 2024-10-23
US20160299128A1 (en) 2016-10-13
MX2014014348A (es) 2015-06-05
CN104520707A (zh) 2015-04-15
US20130316375A1 (en) 2013-11-28
AU2021202609A1 (en) 2021-05-27
JP2015520378A (ja) 2015-07-16
EP2856149A4 (en) 2016-06-01
JP6761827B2 (ja) 2020-09-30
EP2856149B1 (en) 2020-07-08
WO2013177505A1 (en) 2013-11-28
KR20150022878A (ko) 2015-03-04
MX357169B (es) 2018-06-28

Similar Documents

Publication Publication Date Title
US20250237643A1 (en) Diabetes Biomarkers
Couper et al. ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents
Michels et al. Immunologic endocrine disorders
US12006366B2 (en) Methods and compositions for preventing type 1 diabetes
US20200126671A1 (en) Method for determining the risk to develop type 1 diabetes
US11602556B2 (en) Insulin mimotopes and methods of using the same
JP2024535635A (ja) １型糖尿病の処置を予後予測するための方法
Lee et al. Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
US12558336B2 (en) Metabolic rescue of retinal degeneration
Tizazu et al. Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy
Bollyky et al. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention
Jacobs et al. Interferon-β Decreases the Hypermetabolic State of Red Blood Cells from Patients with Multiple Sclerosis
Hosszúfalusi et al. A detailed investigation of maternally inherited diabetes and deafness (MIDD) including clinical characteristics, C‐peptide secretion, HLA‐DR and‐DQ status and autoantibody pattern
Roy et al. Synthetic Immunological Niche Reveals Early Immune Dysregulation and Stratifies Therapeutic Response in Type 1 Diabetes
Pokhrel et al. Autologous serum skin test in chronic idiopathic urticaria
Hill Immunomodulatory responses in the pancreas in health and disease
Welsch Characterization and identification of atypical diabetes in pediatric patients
Almeida Glycans as novel immunomodulators in Idiopathic Inflammatory Myopathies
Guo et al. Calcitriol ameliorates the progression of hepatic fibrosis through autophagy-related gene 16-like 1-mediated autophagy
Boubacar et al. Myasthenia Gravis Associated with Diabetes about an Observation in Dakar, Senegal (West Africa) and Review of the Literature
Gutlić Latent autoimmune diabetes in adults (LADA)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180327

Termination date: 20190524